IMMUNOGENICITY OF RECOMBINANT BCG VACCINES IN RHESUS MONKEYS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 分枝杆菌的特性使它们成为潜在的HIV-1疫苗载体。卡介苗是一种减毒、非致病的牛分枝杆菌，广泛用作结核病和麻风的疫苗。它们也可以很容易地被改造成稳定地表达转基因。然而，由于先前存在的抗卡介苗免疫和较低的抗原表达水平，这些载体的应用受到了限制。在开发出具有增强抗原表达的优化BCG载体后，我们在艾滋病猕猴模型上进行了同源PRIME/BOOST实验和异种重组BCG/重组腺病毒载体方案的测试。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Mycobacteria have features that make them attractive as potential HIV-1 vaccine vectors. The attenuated, non-pathogenic mycobacterium bovis BCG is widely used as a vaccine for tuberculosis and leprosy. They can also be readily engineered to stably express transgenes. However, the utility of these vectors has been limited due to the prevalence of pre-existing anti-BCG immunity and poor antigen expression. After developing optimized BCG vectors with enhanced antigen expression, we test the vectors in the AIDS rhesus monkey model in a homologous prime/boost experiment and in a heterologous recombinant BCG/recombinant Adenovirus vector regimen.